Shopping Cart 0
Cart Subtotal
AED 0

NORTH AMERICA ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTICS INDUSTRY MARKET 2019-2027

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 5505

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 8074

Details

MARKET OUTLOOK

As per the research conducted by Triton, North America Alzheimer's therapeutics and diagnostics market is anticipated to rise at a CAGR of 7.75% in terms of revenue, during the forecast period of 2019-2027.

Ample new cases periodically get registered under cognitive memory loss in the North America region, which has led to a plethora of demands for the development of personalized drugs. This has compelled the respective governments in this region to invest in the R&D for the drugs and diagnostics tests to mitigate the rising rate of neurodegenerative diseases. Thus, these circumstances are expected to bolster the Alzheimer's disease market demand over the forecast period.

The Alzheimer's therapeutics and diagnostics market has two main segments, therapeutics and diagnostics. Stringent government rules for the reimbursement process and inadequate financial conditions of the patients for the treatment are affecting the growth of Alzheimer's therapeutics and diagnostics market in the United States and Canada. The estimations show that Alzheimer's is the sixth leading cause of death in the United States. Fortunately, the rising investment in R&D for personalized medicines and in-vitro diagnostic techniques that involve analyzing the blood and tissues of the specimen in order to provide an optimal cure as well as monitoring the health conditions are expected to proliferate the growth of the North American Alzheimer's therapeutics and diagnostics market.

COMPETITIVE OUTLOOK

The dominant players in the Alzheimer's therapeutic & diagnostic market are AbbVie, Inc., Merck and Co., Axon Neuroscience SE, Siemens Medical Solutions, Baxter International, Inc., GE Healthcare, F. Hoffmann-La Roche AG, Sun Pharma, Pfizer, Inc. and Biogen, Inc.

READ MORE

Table Of Content

Scope

TABLE OF CONTENTS

1. NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET-SUMMARY

2. INDUSTRY OUTLOOK

2.1. MARKET DEFINITION

2.2. PORTER'S FIVE FORCE MODEL

2.2.1. THREAT OF NEW ENTRANTS

2.2.2. THREATS OF SUBSTITUTE PRODUCT

2.2.3. BARGAINING POWER OF BUYER

2.2.4. BARGAINING POWER OF SUPPLIER

2.2.5. INTENSITY OF COMPETITIVE RIVALRY

2.3. VENDOR SCORECARD

2.4. ETYMOLOGY

2.5. PARENT MARKET OUTLOOK

2.6. STRATEGIC BUYING CRITERIA OUTLOOK

2.7. INVESTMENTS OUTLOOK

2.8. KEY FINDINGS

2.9. INDUSTRY STRUCTURE

2.9.1. RESEARCH & DEVELOPMENT

2.9.2. MANUFACTURING

2.9.3. RAW MATERIALS

2.9.4. END-USER

2.9.5. WHOLESALERS

2.10. REGULATORY FRAMEWORK

2.11. THE UNITED STATES REGULATORY AGENCY

2.12. ALZHEIMER'S DISEASE ETIOLOGY

2.13. PIPELINE OUTLOOK

2.14. PHASES AND STERNNESS OF ALZHEIMER'S DISEASE

2.15. MARKET DRIVERS

2.15.1. GROWTH OF THE ALZHEIMER'S DISEASE

2.15.2. INCREASING GERIATRIC POPULATION

2.15.3. SUBSTANTIAL INVESTMENTS BY GOVERNMENT IN RESEARCH

2.16. MARKET RESTRAINTS

2.16.1. STRINGENT GOVERNMENT REGULATIONS

2.16.2. HIGH TREATMENT COSTS OF ALZHEIMER'S DISEASE

2.17. MARKET OPPORTUNITIES

2.17.1. IN-VITRO DIAGNOSTIC TECHNIQUES ARE A BOON TO THE MARKET

2.17.2. INCREASING R&D INVESTMENT IN PERSONALIZED MEDICINES

2.18. MARKET CHALLENGES

2.18.1. LESS AWARENESS ABOUT NEW THERAPIES FOR ALZHEIMER'S DISEASE

2.18.2. VERY FEW SKILLED PROFESSIONALS PERTAINING TO THE TREATMENT OF ALZHEIMER'S DISEASE

3. ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET OUTLOOK-BY THERAPEUTICS AND DIAGNOSTICS

3.1. THERAPEUTICS

3.1.1. THERAPEUTICS BY DRUGS

3.1.1.1. MARKETED DRUGS

3.1.1.2. PIPELINE DRUGS

3.1.2. THERAPEUTICS BY DISEASE STAGE

3.1.2.1. LATE STAGE: SEVERE AD

3.1.2.2. EARLY/MIDDLE STAGE: MILD TO MODERATE AD

3.1.2.3. PRODROMAL STAGE

3.1.3. THERAPEUTICS BY GENERIC AND BRANDED

3.1.3.1. BRANDED

3.1.3.2. GENERIC

3.2. DIAGNOSTICS

3.2.1. LUMBAR PUNCTURE TEST

3.2.2. POSITRON EMISSION TOMOGRAPHY

3.2.3. ELECTROENCEPHALOGRAPHY

3.2.4. MAGNETIC RESONANCE IMAGING

3.2.5. COMPUTED TOMOGRAPHY

3.2.6. OTHER DIAGNOSTICS

4. ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET-REGIONAL OUTLOOK

4.1. THE UNITED STATES

4.2. CANADA

5. COMPETITIVE LANDSCAPE

5.1. ABBVIE, INC.

5.2. BAXTER INTERNATIONAL, INC.

5.3. BIOGEN, INC.

5.4. F. HOFFMANN-LA ROCHE AG

5.5. GE HEALTHCARE

5.6. MERCK AND CO.

5.7. PFIZER, INC.

5.8. PIRAMAL ENTERPRISES, LTD.

5.9. SIEMENS MEDICAL SOLUTIONS

5.10. SUN PHARMA

6. METHODOLOGY AND SCOPE

6.1. RESEARCH SCOPE

6.2. SOURCES OF DATA

6.3. RESEARCH METHODOLOGY

 

 

 

 

TABLE LIST

TABLE 1 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

TABLE 2 DIFFERENT BIOMARKERS RELATED TO THE ALZHEIMER'S DISEASE

TABLE 3 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

TABLE 4 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS BY DRUGS 2019-2027 (USD MILLION)

TABLE 5 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DISEASE STAGE BY DRUGS 2019-2027 (USD MILLION)

TABLE 6 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS BY GENERIC AND BRANDED 2019-2027 (USD MILLION)

TABLE 7 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY TYPES 2019-2027 (USD MILLION)

TABLE 8 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET BY COUNTRY 2019-2027 (USD MILLION)

 

 

 

 

 

 

FIGURE LIST

FIGURE 1 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 2 ALZHEIMER'S DRUGS IN THE PIPELINE BY TREATMENT FOCUS (NUMBER OF DRUGS)

FIGURE 3 PEOPLE SUFFERING FROM ALZHEIMER'S DEMENTIA IN THE UNITED STATES OF DIFFERENT AGES 2017 (%)

FIGURE 4 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS 2019-2027 (USD MILLION)

FIGURE 5 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN MARKETED DRUGS 2019-2027 (USD MILLION)

FIGURE 6 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PIPELINE DRUGS 2019-2027 (USD MILLION)

FIGURE 7 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN LATE STAGE: SEVERE AD 2019-2027 (USD MILLION)

FIGURE 8 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN EARLY/MIDDLE STAGE: MILD TO MODERATE AD 2019-2027 (USD MILLION)

FIGURE 9 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PRODROMAL STAGE 2019-2027 (USD MILLION)

FIGURE 10 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN BRANDED 2019-2027 (USD MILLION)

FIGURE 11 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN GENERIC 2019-2027 (USD MILLION)

FIGURE 12 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DIAGNOSTICS 2019-2027 (USD MILLION)

FIGURE 13 NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN LUMBAR PUNCTURE TEST 2019-2027 (USD MILLION)

FIGURE 14 NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN POSITRON EMISSION TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 15 NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN ELECTROENCEPHALOGRAPHY 2019-2027 (USD MILLION)

FIGURE 16 NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN MAGNETIC RESONANCE IMAGING 2019-2027 (USD MILLION)

FIGURE 17 NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN COMPUTED TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 18 NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN OTHER DIAGNOSTICS 2019-2027 (USD MILLION)

FIGURE 19 THE UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

FIGURE 20 CANADA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027


List Of Figure

FIGURE LIST

FIGURE 1 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 2 ALZHEIMER'S DRUGS IN THE PIPELINE BY TREATMENT FOCUS (NUMBER OF DRUGS)

FIGURE 3 PEOPLE SUFFERING FROM ALZHEIMER'S DEMENTIA IN THE UNITED STATES OF DIFFERENT AGES 2017 (%)

FIGURE 4 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS 2019-2027 (USD MILLION)

FIGURE 5 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN MARKETED DRUGS 2019-2027 (USD MILLION)

FIGURE 6 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PIPELINE DRUGS 2019-2027 (USD MILLION)

FIGURE 7 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN LATE STAGE: SEVERE AD 2019-2027 (USD MILLION)

FIGURE 8 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN EARLY/MIDDLE STAGE: MILD TO MODERATE AD 2019-2027 (USD MILLION)

FIGURE 9 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PRODROMAL STAGE 2019-2027 (USD MILLION)

FIGURE 10 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN BRANDED 2019-2027 (USD MILLION)

FIGURE 11 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN GENERIC 2019-2027 (USD MILLION)

FIGURE 12 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DIAGNOSTICS 2019-2027 (USD MILLION)

FIGURE 13 NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN LUMBAR PUNCTURE TEST 2019-2027 (USD MILLION)

FIGURE 14 NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN POSITRON EMISSION TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 15 NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN ELECTROENCEPHALOGRAPHY 2019-2027 (USD MILLION)

FIGURE 16 NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN MAGNETIC RESONANCE IMAGING 2019-2027 (USD MILLION)

FIGURE 17 NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN COMPUTED TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 18 NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN OTHER DIAGNOSTICS 2019-2027 (USD MILLION)

FIGURE 19 THE UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

FIGURE 20 CANADA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027


List Of Table

TABLE LIST

TABLE 1 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

TABLE 2 DIFFERENT BIOMARKERS RELATED TO THE ALZHEIMER'S DISEASE

TABLE 3 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

TABLE 4 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS BY DRUGS 2019-2027 (USD MILLION)

TABLE 5 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DISEASE STAGE BY DRUGS 2019-2027 (USD MILLION)

TABLE 6 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS BY GENERIC AND BRANDED 2019-2027 (USD MILLION)

TABLE 7 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY TYPES 2019-2027 (USD MILLION)

TABLE 8 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET BY COUNTRY 2019-2027 (USD MILLION)

Licence Rights

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

1. ABBVIE, INC.

2. BAXTER INTERNATIONAL, INC.

3. BIOGEN, INC.

4. F. HOFFMANN-LA ROCHE AG

5. GE HEALTHCARE

6. MERCK AND CO.

7. PFIZER, INC.

8. PIRAMAL ENTERPRISES, LTD.

9. SIEMENS MEDICAL SOLUTIONS

10. SUN PHARMA

Company Profile

Company Profile Title

MARKET OUTLOOK

As per the research conducted by Triton, North America Alzheimer's therapeutics and diagnostics market is anticipated to rise at a CAGR of 7.75% in terms of revenue, during the forecast period of 2019-2027.

Ample new cases periodically get registered under cognitive memory loss in the North America region, which has led to a plethora of demands for the development of personalized drugs. This has compelled the respective governments in this region to invest in the R&D for the drugs and diagnostics tests to mitigate the rising rate of neurodegenerative diseases. Thus, these circumstances are expected to bolster the Alzheimer's disease market demand over the forecast period.

The Alzheimer's therapeutics and diagnostics market has two main segments, therapeutics and diagnostics. Stringent government rules for the reimbursement process and inadequate financial conditions of the patients for the treatment are affecting the growth of Alzheimer's therapeutics and diagnostics market in the United States and Canada. The estimations show that Alzheimer's is the sixth leading cause of death in the United States. Fortunately, the rising investment in R&D for personalized medicines and in-vitro diagnostic techniques that involve analyzing the blood and tissues of the specimen in order to provide an optimal cure as well as monitoring the health conditions are expected to proliferate the growth of the North American Alzheimer's therapeutics and diagnostics market.

COMPETITIVE OUTLOOK

The dominant players in the Alzheimer's therapeutic & diagnostic market are AbbVie, Inc., Merck and Co., Axon Neuroscience SE, Siemens Medical Solutions, Baxter International, Inc., GE Healthcare, F. Hoffmann-La Roche AG, Sun Pharma, Pfizer, Inc. and Biogen, Inc.

READ MORE

Scope

TABLE OF CONTENTS

1. NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET-SUMMARY

2. INDUSTRY OUTLOOK

2.1. MARKET DEFINITION

2.2. PORTER'S FIVE FORCE MODEL

2.2.1. THREAT OF NEW ENTRANTS

2.2.2. THREATS OF SUBSTITUTE PRODUCT

2.2.3. BARGAINING POWER OF BUYER

2.2.4. BARGAINING POWER OF SUPPLIER

2.2.5. INTENSITY OF COMPETITIVE RIVALRY

2.3. VENDOR SCORECARD

2.4. ETYMOLOGY

2.5. PARENT MARKET OUTLOOK

2.6. STRATEGIC BUYING CRITERIA OUTLOOK

2.7. INVESTMENTS OUTLOOK

2.8. KEY FINDINGS

2.9. INDUSTRY STRUCTURE

2.9.1. RESEARCH & DEVELOPMENT

2.9.2. MANUFACTURING

2.9.3. RAW MATERIALS

2.9.4. END-USER

2.9.5. WHOLESALERS

2.10. REGULATORY FRAMEWORK

2.11. THE UNITED STATES REGULATORY AGENCY

2.12. ALZHEIMER'S DISEASE ETIOLOGY

2.13. PIPELINE OUTLOOK

2.14. PHASES AND STERNNESS OF ALZHEIMER'S DISEASE

2.15. MARKET DRIVERS

2.15.1. GROWTH OF THE ALZHEIMER'S DISEASE

2.15.2. INCREASING GERIATRIC POPULATION

2.15.3. SUBSTANTIAL INVESTMENTS BY GOVERNMENT IN RESEARCH

2.16. MARKET RESTRAINTS

2.16.1. STRINGENT GOVERNMENT REGULATIONS

2.16.2. HIGH TREATMENT COSTS OF ALZHEIMER'S DISEASE

2.17. MARKET OPPORTUNITIES

2.17.1. IN-VITRO DIAGNOSTIC TECHNIQUES ARE A BOON TO THE MARKET

2.17.2. INCREASING R&D INVESTMENT IN PERSONALIZED MEDICINES

2.18. MARKET CHALLENGES

2.18.1. LESS AWARENESS ABOUT NEW THERAPIES FOR ALZHEIMER'S DISEASE

2.18.2. VERY FEW SKILLED PROFESSIONALS PERTAINING TO THE TREATMENT OF ALZHEIMER'S DISEASE

3. ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET OUTLOOK-BY THERAPEUTICS AND DIAGNOSTICS

3.1. THERAPEUTICS

3.1.1. THERAPEUTICS BY DRUGS

3.1.1.1. MARKETED DRUGS

3.1.1.2. PIPELINE DRUGS

3.1.2. THERAPEUTICS BY DISEASE STAGE

3.1.2.1. LATE STAGE: SEVERE AD

3.1.2.2. EARLY/MIDDLE STAGE: MILD TO MODERATE AD

3.1.2.3. PRODROMAL STAGE

3.1.3. THERAPEUTICS BY GENERIC AND BRANDED

3.1.3.1. BRANDED

3.1.3.2. GENERIC

3.2. DIAGNOSTICS

3.2.1. LUMBAR PUNCTURE TEST

3.2.2. POSITRON EMISSION TOMOGRAPHY

3.2.3. ELECTROENCEPHALOGRAPHY

3.2.4. MAGNETIC RESONANCE IMAGING

3.2.5. COMPUTED TOMOGRAPHY

3.2.6. OTHER DIAGNOSTICS

4. ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET-REGIONAL OUTLOOK

4.1. THE UNITED STATES

4.2. CANADA

5. COMPETITIVE LANDSCAPE

5.1. ABBVIE, INC.

5.2. BAXTER INTERNATIONAL, INC.

5.3. BIOGEN, INC.

5.4. F. HOFFMANN-LA ROCHE AG

5.5. GE HEALTHCARE

5.6. MERCK AND CO.

5.7. PFIZER, INC.

5.8. PIRAMAL ENTERPRISES, LTD.

5.9. SIEMENS MEDICAL SOLUTIONS

5.10. SUN PHARMA

6. METHODOLOGY AND SCOPE

6.1. RESEARCH SCOPE

6.2. SOURCES OF DATA

6.3. RESEARCH METHODOLOGY

 

 

 

 

TABLE LIST

TABLE 1 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

TABLE 2 DIFFERENT BIOMARKERS RELATED TO THE ALZHEIMER'S DISEASE

TABLE 3 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

TABLE 4 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS BY DRUGS 2019-2027 (USD MILLION)

TABLE 5 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DISEASE STAGE BY DRUGS 2019-2027 (USD MILLION)

TABLE 6 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS BY GENERIC AND BRANDED 2019-2027 (USD MILLION)

TABLE 7 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY TYPES 2019-2027 (USD MILLION)

TABLE 8 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET BY COUNTRY 2019-2027 (USD MILLION)

 

 

 

 

 

 

FIGURE LIST

FIGURE 1 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 2 ALZHEIMER'S DRUGS IN THE PIPELINE BY TREATMENT FOCUS (NUMBER OF DRUGS)

FIGURE 3 PEOPLE SUFFERING FROM ALZHEIMER'S DEMENTIA IN THE UNITED STATES OF DIFFERENT AGES 2017 (%)

FIGURE 4 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS 2019-2027 (USD MILLION)

FIGURE 5 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN MARKETED DRUGS 2019-2027 (USD MILLION)

FIGURE 6 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PIPELINE DRUGS 2019-2027 (USD MILLION)

FIGURE 7 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN LATE STAGE: SEVERE AD 2019-2027 (USD MILLION)

FIGURE 8 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN EARLY/MIDDLE STAGE: MILD TO MODERATE AD 2019-2027 (USD MILLION)

FIGURE 9 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PRODROMAL STAGE 2019-2027 (USD MILLION)

FIGURE 10 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN BRANDED 2019-2027 (USD MILLION)

FIGURE 11 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN GENERIC 2019-2027 (USD MILLION)

FIGURE 12 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DIAGNOSTICS 2019-2027 (USD MILLION)

FIGURE 13 NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN LUMBAR PUNCTURE TEST 2019-2027 (USD MILLION)

FIGURE 14 NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN POSITRON EMISSION TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 15 NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN ELECTROENCEPHALOGRAPHY 2019-2027 (USD MILLION)

FIGURE 16 NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN MAGNETIC RESONANCE IMAGING 2019-2027 (USD MILLION)

FIGURE 17 NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN COMPUTED TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 18 NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN OTHER DIAGNOSTICS 2019-2027 (USD MILLION)

FIGURE 19 THE UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

FIGURE 20 CANADA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027


List Of Figure

FIGURE LIST

FIGURE 1 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 2 ALZHEIMER'S DRUGS IN THE PIPELINE BY TREATMENT FOCUS (NUMBER OF DRUGS)

FIGURE 3 PEOPLE SUFFERING FROM ALZHEIMER'S DEMENTIA IN THE UNITED STATES OF DIFFERENT AGES 2017 (%)

FIGURE 4 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS 2019-2027 (USD MILLION)

FIGURE 5 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN MARKETED DRUGS 2019-2027 (USD MILLION)

FIGURE 6 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PIPELINE DRUGS 2019-2027 (USD MILLION)

FIGURE 7 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN LATE STAGE: SEVERE AD 2019-2027 (USD MILLION)

FIGURE 8 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN EARLY/MIDDLE STAGE: MILD TO MODERATE AD 2019-2027 (USD MILLION)

FIGURE 9 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PRODROMAL STAGE 2019-2027 (USD MILLION)

FIGURE 10 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN BRANDED 2019-2027 (USD MILLION)

FIGURE 11 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN GENERIC 2019-2027 (USD MILLION)

FIGURE 12 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DIAGNOSTICS 2019-2027 (USD MILLION)

FIGURE 13 NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN LUMBAR PUNCTURE TEST 2019-2027 (USD MILLION)

FIGURE 14 NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN POSITRON EMISSION TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 15 NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN ELECTROENCEPHALOGRAPHY 2019-2027 (USD MILLION)

FIGURE 16 NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN MAGNETIC RESONANCE IMAGING 2019-2027 (USD MILLION)

FIGURE 17 NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN COMPUTED TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 18 NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN OTHER DIAGNOSTICS 2019-2027 (USD MILLION)

FIGURE 19 THE UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

FIGURE 20 CANADA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027


List Of Table

TABLE LIST

TABLE 1 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

TABLE 2 DIFFERENT BIOMARKERS RELATED TO THE ALZHEIMER'S DISEASE

TABLE 3 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

TABLE 4 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS BY DRUGS 2019-2027 (USD MILLION)

TABLE 5 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DISEASE STAGE BY DRUGS 2019-2027 (USD MILLION)

TABLE 6 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS BY GENERIC AND BRANDED 2019-2027 (USD MILLION)

TABLE 7 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY TYPES 2019-2027 (USD MILLION)

TABLE 8 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET BY COUNTRY 2019-2027 (USD MILLION)

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

1. ABBVIE, INC.

2. BAXTER INTERNATIONAL, INC.

3. BIOGEN, INC.

4. F. HOFFMANN-LA ROCHE AG

5. GE HEALTHCARE

6. MERCK AND CO.

7. PFIZER, INC.

8. PIRAMAL ENTERPRISES, LTD.

9. SIEMENS MEDICAL SOLUTIONS

10. SUN PHARMA